palexia depot 250 mg
grünenthal gmbh - tapentadolhydroklorid - depottablett - 250 mg
trampalgin 37.5 mg / 325 mg
karo pharma as - tramadolhydroklorid / paracetamol - tablett - 37.5 mg / 325 mg
palexia 20 mg/ ml
grünenthal gmbh - tapentadolhydroklorid - mikstur, oppløsning - 20 mg/ ml
palexia 4 mg/ ml
grünenthal gmbh - tapentadolhydroklorid - mikstur, oppløsning - 4 mg/ ml
tapentadol medical valley 250 mg
medical valley invest ab - tapentadoltartrat - depottablett - 250 mg
tapentadol medical valley 50 mg
medical valley invest ab - tapentadoltartrat - depottablett - 50 mg
tapentadol medical valley 100 mg
medical valley invest ab - tapentadoltartrat - depottablett - 100 mg
tapentadol medical valley 150 mg
medical valley invest ab - tapentadoltartrat - depottablett - 150 mg
tapentadol medical valley 200 mg
medical valley invest ab - tapentadoltartrat - depottablett - 200 mg
instanyl
takeda pharma a/s - fentanyl citrate - pain; cancer - analgetika - instanyl er indisert for behandling av gjennombrudd smerte hos voksne allerede mottar vedlikehold opioid terapi for kronisk kreft smerter. gjennombruddssmerter er en forbigående forverring av smerte som oppstår på bakgrunn av ellers kontrollert vedvarende smerte. patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.